Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Transcode Therapeutics Inc (NQ: RNAZ ) 0.4700 +0.0010 (+0.21%) Streaming Delayed Price Updated: 3:59 PM EST, Nov 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Transcode Therapeutics Inc < Previous 1 2 3 Next > TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance November 05, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data October 23, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology October 10, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate September 17, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer September 10, 2024 Study demonstrates that TransCode’s lead therapeutic candidate, TTX-MC138, reduces tumor cell capacity for self-renewal From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate September 05, 2024 Grant awarded by the National Cancer Institute (NCI) of the NIH to support clinical development of lead therapeutic candidate, TTX-MC138 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation August 15, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics, Inc. Announces Closing of Public Offering July 24, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics, Inc. Announces Pricing of Public Offering July 22, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock July 22, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements June 10, 2024 TransCode shares to remain listed on Nasdaq From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138 May 29, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Open Letter to Shareholders May 13, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors April 15, 2024 Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Reports 2023 Results; Provides Business Update April 03, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer March 28, 2024 Medical oncologist brings over 25 years of industry experience to lead Clinical Development Strategy From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment March 11, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress March 06, 2024 Highlights TTX-MC138’s Path from Target Discovery to the Clinic From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic February 20, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market January 31, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer January 29, 2024 Project to test combination of TransCode’s proprietary TTX delivery platform and Debiopharm’s drug delivery technologies From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Closing of $7.25 Million Public Offering January 22, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering January 18, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO January 12, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces 1-for-40 Reverse Stock Split January 11, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives January 04, 2024 Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A First-in-Class Compound Designed to Treat Metastatic... From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138 December 12, 2023 TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium December 05, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules December 04, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules November 30, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
